Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The remit of the Genetic Modification Safety (GMSC) committee has expanded to include approval of Advanced Therapy Medicinal Products (ATMP) (including gene therapy medicinal products (GTMPs)) for clinical deployment & clinical research.  The committee will now be run jointly between the Oxford University Hospital (OUH) and University of Oxford (UOXF). 

For communication and submissions for approval please email the specific email box: ATMP&GMSCcommitteeOUH/UOXF@oxnet.nhs.uk.

Dr Katie Jeffery and Prof Nicola Stoner are the joint chairs of the committee which reports to the Medicines Management and Therapeutics Committee (MMTC) in OUH and the joint R&D committee (OUH/UOXF).